Evidence map›Paper›PMID 42513123›Full record

ReviewMolecules (Basel, Switzerland)2026

Recent Progress in the Sustainable Synthesis of Imidazole Derivatives: Advances in Multicomponent Reactions, Catalysis, and Green Chemistry.

Altynay B Kaldybayeva, Timur T Shapinov, Feyyaz Durap, Valentina K Yu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Altynay B KaldybayevaDepartment of Chemistry and Technology of Organic Substances, Natural Compounds and Polymers, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan.ORCID 0000-0003-2805-3633
Timur T ShapinovSchool of Chemical Engineering, Kazakh-British Technical University, Almaty 050000, Kazakhstan.ORCID 0009-0008-3588-2337
Feyyaz DurapDepartment of Chemistry, Dicle University, Diyarbakir 21280, Turkey.ORCID 0000-0003-0899-1948
Valentina K YuLaboratory of Chemistry of Synthetic and Natural Medicinal Compounds, A.B. Bekturov Institute of Chemical Sciences, Almaty 050010, Kazakhstan.ORCID 0000-0001-6508-707X

Funding

The Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP22688235
6 · The paper itself

Abstract

Imidazole derivatives represent a privileged class of nitrogen-containing heterocycles that continue to attract considerable attention owing to their structural versatility, synthetic accessibility, and wide range of applications in medicinal chemistry, materials science, catalysxis, and corrosion inhibition. In recent years, significant efforts have been directed towards the development of efficient, sustainable, and experimentally simple synthetic methodologies for substituted imidazoles. This review summarizes and critically evaluates recent advances (mainly from 2021 onward) in the synthesis of imidazole derivatives, with particular emphasis on multicomponent reactions, especially the Debus-Radziszewski condensation. Catalyst-free protocols, organocatalysts, metal-based catalysts, nanocatalysts, and ionic liquids are systematically discussed and compared. In addition, alternative two- and three-component strategies that enable access to nonclassical substitution patterns are reviewed. The advantages and limitations of each approach are highlighted with respect to reaction efficiency, substrate scope, sustainability, and practical applicability. This review aims to serve as a comprehensive reference for synthetic chemists seeking rational strategies for the preparation of structurally diverse imidazole derivatives.

Indexed as

catalysisDebus–Radziszewski reactiongreen synthesisheterocyclesimidazole derivativesmulticomponent reactions

Identifiers

PMID42513123
PMCPMC13416273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.